![]() ![]() Food and Drug Administration (FDA) has approved a PD-1 inhibitor for the treatment of adult and pediatric patients with MSI-H or MMR solid tumors, regardless of tissue type. The latest research data supports this hypothesis, and MMR deficient cancers are sensitive to immune checkpoint inhibitors, regardless of cancer type (3).Īs a result of MSI studies in cancer research, the U.S. ![]() MMR-deficient colorectal cancer is hypothesized to have a larger proportion of neoantigens that would make it more sensitive to immunotherapy. Studies have shown that colorectal cancers with MMR deficiency (MSI-H) are sensitive to immune checkpoint blockade with antibodies to programmed death receptor-1 (PD-1) (5,6). The Bethesda guidelines and MSI testing have helped with patient prognosis, guiding therapy and serving as a screen for HNPCC. Known as the revised Bethesda guidelines, these recommendations established microsatellite targets in the testing panel (e.g., BAT25, BAT26) and defined how one would classify a cancer tumor as microsatellite stable (MSS), MSI-low (MSI-L), and MSI-high (MSI-H) based on the number of biomarkers found with a mutation. Given the prevalence of MSI in colorectal cancer and the need to better understand both clinical and histological manifestations, recommended MSI testing criteria were established by key leaders in the field (4). Analyzing MSI is becoming an increasingly important tool in cancer research and immuno-oncology.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |